Human papillomavirus vaccines in development: If they're successful in clinical trials, how will they be implemented?

Gynecologic Oncology

Volumn 99, Issue 3 SUPPL., 2005, Pages

  Shaw, Alan R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cervical cancer; CIN; HPV; HPV vaccines; Prophylactic vaccines; SIL; Vaccine implementation

Indexed keywords

UNCLASSIFIED DRUG; VERRUCA VACCINE; VIRUS VACCINE;

ANTIBODY RESPONSE; CONDYLOMA; CONFERENCE PAPER; DRUG EFFECT; GENOTYPE; HUMAN; HUMAN PAPILLOMA VIRUS INFECTION; IMMUNIZATION; PRIORITY JOURNAL; PROPHYLAXIS; VIRUS INFECTION; VIRUS TYPING; WART VIRUS;

CLINICAL TRIALS; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINATION; VIRAL VACCINES;

EID: 28844451139     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.07.097     Document Type: Conference Paper

References (2)

1. L.L. Villa, R.L.R Costa, C.A. Petta, R.P. Andrade, K.A. Ault, L.L. Guiliano and the Merck Vaccine Group Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled mulitcentre phase II efficacy trial Lancet. Oncol. 6 2005 271 278
2. D.M. Harper for the GlaxoSmithKline HPV Vaccine Study Group Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial Lancet 364 2004 1757 1765